Palvella Therapeutics, Inc.
PVLAHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Palvella Therapeutics, Inc. (PVLA) is listed under Biotechnology. The $1.80B market capitalization puts PVLA squarely in small-cap range for its industry. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Market Cap
$1.80B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-15.68
EPS (TTM)
$-4.79
EPS (Fwd)
$-7.98
ROE
-46.6%
ROA
-22.1%
Cash
$250.6M
Total Debt
$22.6M
Free CF
-$25.4M
52W Change
71.4%
Annual Financials
Cash vs Debt
Where PVLA stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, PVLA finished 8.02% below its 150-day moving average ($133.27) and 1.91% below its 200-day moving average ($124.97). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PVLA overbought or oversold?
At the October 15, 2026 close, PVLA's RSI(14) was 25.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Palvella Therapeutics, Inc. holds $250.6M in cash against $22.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$25.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -46.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, PVLA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Palvella Therapeutics, Inc. and its sector.